Advertisement

HF-564-01 READMISSION OUTCOMES IN PATIENTS WITH CARDIAC SARCOIDOSIS

      Background

      Sarcoidosis is a multi-system disorder which can affect the lungs, lymph nodes, liver, spleen, skin, nervous system and the heart. Cardiac sarcoidosis (CS) has historically been under-diagnosed but continues to be associated with significant morbidity and mortality. The most common presenting symptoms include advanced atrioventricular block, ventricular tachycardia (VT) and heart failure (HF).

      Objective

      To evaluate the incidence and impact of VT and HF on the rates of readmissions in patients with a known diagnosis of sarcoidosis using a real-world database.

      Methods

      Patients with a diagnosis of sarcoidosis with and without admitting symptoms of ventricular tachycardia and/or heart failure from 2010-2017 were abstracted using International Classification of Diseases-9th and 10th Revision-Clinical Modification from the Nationwide Readmissions Database (NRD). All patients >18 years of age with sarcoidosis were included. We excluded patients who were transferred/died at first admission. Patient demographics, presence of comorbidities and time from discharge to readmission were also evaluated.

      Results

      During 2010-2017, 124,695 patients with sarcoidosis were included. Ventricular tachycardia (VT) was the presenting complaint in 2,494 (2.0%) patients whilst heart failure was present in 24,794 (19.9%) patients respectively. Readmission was 4.8% higher (24.8% vs 20.0%, p<0.0001) at 90-days follow-up in patients who had initially presented with VT as compared to those who did not initially present with a VT. Similarly, patients with a diagnosis of heart failure and sarcoidosis were more likely to be readmitted within 90-days follow-up as compared to patients with sarcoidosis without heart failure (29.8% vs 17.7%, p<0.0001).